journal article·2023-12

Controllable Star Cationic Poly(Disulfide)s Achieve Genetically Cascade Catalytic Therapy by Delivering Bifunctional Fusion Plasmids

Dan Yu, Yuanchen Wang, Shuang Qu, Na Zhang, Kaili Nie, Junkai Wang, Yichun Huang, Dandan Sui, Bingran Yu, Meng Qin, Fu‐Jian Xu

Advanced Materials· Volume 35· Issue 52
Publisher page

Abstract

Abstract The absence of effective delivery vectors and suitable multifunctional plasmids limits cancer gene therapy development. The star cationic poly(disulfide)s with β‐cyclodextrin cores (termed β‐CD‐g‐PSSn) for caveolae‐mediated endocytosis are designed and prepared via mild and controllable disulfide exchange polymerization for high‐efficacy cancer therapy. Then, β‐CD‐g‐PSSn/pDNA complexes are transported to the Golgi apparatus and endoplasmic reticulum. Disulfides in β‐CD‐g‐PSSn vectors are degraded by glutathione in tumor cells, which not only promotes intracellular pDNA release but also reduces in vitro and in vivo toxicity. One bifunctional fusion plasmid pCATKR, which expresses catalase (CAT) fused to KillerRed (KR) (CATKR) in the same target cell, is also proposed for genetically cascade catalytic therapy. When compared with pCAT‐KR (plasmid expressing CAT and KR separately in the same cell), delivered pCATKR decomposes hydrogen peroxide, alleviates tumor hypoxia more effectively, generates stronger reactive oxygen species (ROS) capabilities under moderate irradiation, and leads to robust antitumor cascade photodynamic effects. These impressive results are attributed to fusion protein design, which shortens the distance between CAT and KR catalytic centers and leads to improved ROS production efficiency. This work provides a promising strategy by delivering a catalytic cascade functional plasmid via a high‐performance vector with biodegradable and caveolae‐mediated endocytosis characteristics.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Chemical Resource Engineering Key Lab of Biomedical Materials of Natural Macromolecules (Beijing University of Chemical Technology Ministry of Education) and Laboratory of Biomedical Materials Beijing University of Chemical Technology Beijing 100029 China

Cancer Center and National Chengdu Center for Safety Evaluation of Drugs State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu Sichuan 610041 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Beijing Municipality

References (57)

Show source-provided references
1. 10.1002/adma.20200618910.1002/adma.202006189 ↗
2. 10.1016/j.chempr.2019.08.01510.1016/j.chempr.2019.08.015 ↗
3. 10.1038/s41563-022-01251-z10.1038/s41563-022-01251-z ↗
4. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
5. 10.1016/j.ymthe.2020.01.00110.1016/j.ymthe.2020.01.001 ↗
6. 10.1038/s41467-021-26695-w10.1038/s41467-021-26695-w ↗
7. 10.1038/s41551-020-00623-710.1038/s41551-020-00623-7 ↗
8. 10.3390/pharmaceutics1303042810.3390/pharmaceutics13030428 ↗
9. 10.1021/acs.chemrev.0c0099710.1021/acs.chemrev.0c00997 ↗
10. 10.1007/s12274-018-2093-x10.1007/s12274-018-2093-x ↗
11. 10.1016/j.biomaterials.2020.12003110.1016/j.biomaterials.2020.120031 ↗
12. 10.1016/j.jconrel.2014.06.03810.1016/j.jconrel.2014.06.038 ↗
13. 10.1016/j.addr.2019.04.00810.1016/j.addr.2019.04.008 ↗
14. 10.1038/s41565-019-0485-z10.1038/s41565-019-0485-z ↗
15. 10.1021/nn304218q10.1021/nn304218q ↗
16. 10.1021/mp200583d10.1021/mp200583d ↗
17. 10.1021/acs.biomac.7b0169310.1021/acs.biomac.7b01693 ↗
18. 10.1002/adhm.20170114310.1002/adhm.201701143 ↗
19. 10.1039/C8QM00570B10.1039/C8QM00570B ↗
20. 10.1002/marc.20180020710.1002/marc.201800207 ↗
21. 10.1016/j.biomaterials.2016.08.02510.1016/j.biomaterials.2016.08.025 ↗
22. 10.1038/nmat318710.1038/nmat3187 ↗
23. 10.1002/smll.20180306110.1002/smll.201803061 ↗
24. 10.1021/acsami.9b0854410.1021/acsami.9b08544 ↗
25. 10.1002/smll.20190401710.1002/smll.201904017 ↗
26. 10.1002/anie.20181366510.1002/anie.201813665 ↗
27. 10.1002/anie.20190099310.1002/anie.201900993 ↗
28. 10.1021/jacs.9b0038710.1021/jacs.9b00387 ↗
29. 10.1021/ja501581b10.1021/ja501581b ↗
30. 10.1021/jacs.5b0813010.1021/jacs.5b08130 ↗
31. 10.1002/hlca.20170026610.1002/hlca.201700266 ↗
32. 10.1002/chem.20220402110.1002/chem.202204021 ↗
33. 10.1002/anie.20220053510.1002/anie.202200535 ↗
34. 10.1002/adma.20220406510.1002/adma.202204065 ↗
35. 10.1039/C7PY00666G10.1039/C7PY00666G ↗
36. 10.1016/j.matt.2020.10.00210.1016/j.matt.2020.10.002 ↗
37. 10.1016/j.addr.2017.06.00310.1016/j.addr.2017.06.003 ↗
38. 10.1016/j.molcel.2016.07.00810.1016/j.molcel.2016.07.008 ↗
39. 10.1021/ja405617c10.1021/ja405617c ↗
40. 10.1038/s41551-020-00627-310.1038/s41551-020-00627-3 ↗
41. 10.1016/j.tips.2021.01.00510.1016/j.tips.2021.01.005 ↗
42. 10.1002/adma.20210110810.1002/adma.202101108 ↗
43. 10.3390/ijms2122880010.3390/ijms21228800 ↗
44. 10.1016/j.biomaterials.2013.09.07510.1016/j.biomaterials.2013.09.075 ↗
45. 10.1016/j.freeradbiomed.2019.12.00810.1016/j.freeradbiomed.2019.12.008 ↗
46. 10.1021/acs.nanolett.0c0227210.1021/acs.nanolett.0c02272 ↗
47. 10.1016/j.biomaterials.2018.08.01110.1016/j.biomaterials.2018.08.011 ↗
48. 10.1021/ja311961k10.1021/ja311961k ↗
49. 10.1073/pnas.080176310510.1073/pnas.0801763105 ↗
50. 10.1021/acsnano.0c0859610.1021/acsnano.0c08596 ↗
51. 10.1021/mp900282e10.1021/mp900282e ↗
52. 10.1016/j.biomaterials.2012.06.03710.1016/j.biomaterials.2012.06.037 ↗
53. 10.1002/smll.20180020110.1002/smll.201800201 ↗
54. 10.1021/cr300358b10.1021/cr300358b ↗
55. 10.1038/s41565-020-0639-z10.1038/s41565-020-0639-z ↗
56. 10.1002/adfm.20210035510.1002/adfm.202100355 ↗
57. 10.1016/j.biomaterials.2020.11975510.1016/j.biomaterials.2020.119755 ↗